ClinicalTrials.gg
CompletedNCT02565277Updated Oct 5, 2026

The Effect of Influenza Vaccination on the Systemic Inflammatory Response and Myocardial Protection in Patients Undergoing Cardiac Surgery: a Randomized Controlled Trial

A Phase 4 interventional study of Influenza Vaccine and Placebo in Systemic Inflammatory Response, sponsored by Health Sciences North Research Institute. Completed at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Health Sciences North Research Institute · Phase 4, Interventional, and Other

How we know

Updated Oct 5, 20261 site added1 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

To assess the impact of influenza vaccination on the overall systemic inflammatory response in patients undergoing cardiac surgery and investigate functional and clinical outcomes in vaccinated patients postoperatively.

Read the detailed description

The investigators propose to perform a single center, double-blind, randomized, placebo-controlled crossover trial analyzing the beneficial effect of the influenza vaccine in patients undergoing cardiac surgery. This study assesses the impact of the influenza vaccination on the overall systemic inflammatory response and investigates the functional and clinical outcome in vaccinated patients after cardiac surgery. The study sample will consist of patients undergoing cardiac surgery at Health Sciences North randomized into 2 groups: 1) those who receive the vaccine or placebo preoperatively, or: 2) those who receive the vaccine or placebo 4-6 weeks postoperatively. Subjects in both groups will be compared using standard laboratory tools to assess the level of various pro- and anti-inflammatory cytokines (IL-6, IL-8,TNF-alpha, IL-10) as well as other cardiac and inflammatory markers (troponins, CRP), at different time intervals intra- and post-operatively. Other clinical outcomes will also be collected prospectively and compared between the 2 groups. These include hemodynamic parameters as well as major postoperative events. Further assessments will include the Frailty Index and Scale (in patients 65+) and length of stay after surgery

02

Conditions studied

  • Systemic Inflammatory Response
03

In context

Lead sponsor

Health Sciences North Research Institute is the lead sponsor of 10 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who the investigator believes can and will comply with the requirements of the protocol (i.e. return for follow-up visits, and able to converse with study personnel)
  • Age 18 years or older
  • Undergoing major cardiac surgery using cardiopulmonary bypass

Exclusion criteria

Exclusion Criteria:

  • Have not received influenza vaccination in the past or cannot be vaccinated due to previous severe reaction to influenza vaccine, egg, latex, or thimerosol allergies, or refusal of vaccination
  • Participant has received a community available influenza vaccine within \<6 months
  • History of Guillain-Barré syndrome
  • disorders or medications (including oral prednisone >10 mg daily, recent chemotherapy treatment)
  • Emergency cases as determined by the investigator or physician
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
30 participants (actual)

Study arms

  • Active comparator
    Influenza Vaccine

    Fluzone injection once IM

    Biological: Influenza Vaccine

  • Placebo comparator
    Placebo

    Saline Injection once IM

    Drug: Placebo

Interventions

  • BiologicalInfluenza Vaccine

    Also known as: Fluzone

  • DrugPlacebo

    Also known as: Saline Injection

06

What researchers measure

Primary outcomes

  1. Pro and anti-inflammatory cytokines and inflammatory markers

    Time frame: Nine Months

07

Study locations

1 site
  • Health Sciences North Research Institute
    Greater Sudbury, Ontario P3E5J1, Canada
08

Timeline

1 registry update since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2015, a primary completion of Dec 2018 and a completion of Dec 2018. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2015
First posted
Oct 1, 2015
Start
Sep 2015
Primary completionActual
Dec 25, 2018
CompletionActual
Dec 25, 2018
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Health Sciences North Research Institute · Greater Sudbury, Canada
Show 1 removed
  • Health Sciences North Research Institute · Sudbury, Canada
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    1 site added, 1 site removed
    Show site
    • Health Sciences North Research Institute · Greater Sudbury, Canada
    Show 1 removed
    • Health Sciences North Research Institute · Sudbury, Canada
    + 3 other changes: index terms, responsible party and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT02565277
Lead sponsor
Health Sciences North Research Institute
Responsible party
Sponsor
First posted
Oct 1, 2015
Start date
Sep 2015
Primary completion
Dec 25, 2018
Completion
Dec 25, 2018
Last update
Oct 5, 2026

Study contacts

Roni E Atoui, MSc MD FRCSC
principal investigator · Health Sciences North Research Institute

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion